All In Biotech

Drug Trial Radar · NCT05950464

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

A Phase 1B Study of Combination ATR (M1774) and BET Inhibition (ZEN003694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

65

Planned (sponsor's estimate)

Start

Dec 18, 2023

Primary completion

Jun 30, 2027

Study completion Jun 30, 2027

Sponsor

Sponsor type
NIH
Collaborators
NRG Oncology
First posted
Jul 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase Ib trial tests the safety, side effects, and best dose of M1774 when given with ZEN-3694 in treating patients with ovarian and endometrial cancer that has come back (recurrent). M1774 and ZEN-3694 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. M1774 and ZEN-3694 combined together has demonstrated to be better than either drug alone in killing ovarian tumor cells.

Conditions

  • Recurrent Endometrial Carcinoma
  • Recurrent Endometrial Clear Cell Adenocarcinoma
  • Recurrent Endometrial Endometrioid Adenocarcinoma
  • Recurrent Endometrial Low Grade Endometrioid Adenocarcinoma
  • Recurrent Ovarian Clear Cell Adenocarcinoma
  • Recurrent Ovarian Endometrioid Adenocarcinoma
  • Recurrent Ovarian High Grade Serous Adenocarcinoma
  • Recurrent Ovarian Low Grade Endometrioid Adenocarcinoma
  • Recurrent Platinum-Resistant Ovarian Carcinoma

Interventions

  • BET Bromodomain Inhibitor ZEN-3694Drug

    Given PO

  • Biopsy ProcedureProcedure

    Undergo biopsy

  • Biospecimen CollectionProcedure

    Undergo collection of blood samples

  • Computed TomographyProcedure

    Undergo CT

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • TuvusertibDrug

    Given PO

  • X-Ray ImagingProcedure

    Undergo x-ray

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicities (DLTs) (Part I)Time frame: Within the first cycle of study treatment (up to 28 days)
  2. DLTs (Part II)Time frame: Within the first 2 cycles of study treatment (up to 56 days)
  3. Measurements for gammaH2AX (PART II)Time frame: Baseline and cycle 1, day 8 (C1D8)
  4. Incidence of adverse events (Part I and II)Time frame: Up to 5 years

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Augusta University Medical Center

    Augusta, Georgia · Recruiting

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois · Recruiting

  • University of Iowa/Holden Comprehensive Cancer Center

    Iowa City, Iowa · Recruiting

  • Wayne State University/Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • University of New Mexico Cancer Center

    Albuquerque, New Mexico · Recruiting

  • Case Western Reserve University

    Cleveland, Ohio · Active not recruiting

  • Cleveland Clinic Foundation

    Cleveland, Ohio · Recruiting

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma · Recruiting

  • NRG Oncology

    Philadelphia, Pennsylvania · Recruiting

  • University of Pennsylvania/Abramson Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania · Recruiting

  • Women and Infants Hospital

    Providence, Rhode Island · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.